Acrivon Therapeutics (ACRV) Competitors $1.32 -0.03 (-2.22%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.35 +0.03 (+2.20%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. DMAC, NVCT, CGEN, ACRS, BIOA, MOLN, ALEC, VTYX, LXEO, and THTXShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include DiaMedica Therapeutics (DMAC), Nuvectis Pharma (NVCT), Compugen (CGEN), Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), and Theratechnologies (THTX). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors DiaMedica Therapeutics Nuvectis Pharma Compugen Aclaris Therapeutics BioAge Labs Molecular Partners Alector Ventyx Biosciences Lexeo Therapeutics Theratechnologies Acrivon Therapeutics (NASDAQ:ACRV) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment. Do institutionals & insiders believe in ACRV or DMAC? 71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 11.9% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend ACRV or DMAC? Acrivon Therapeutics currently has a consensus price target of $17.71, indicating a potential upside of 1,241.99%. DiaMedica Therapeutics has a consensus price target of $8.00, indicating a potential upside of 120.39%. Given Acrivon Therapeutics' higher possible upside, equities analysts plainly believe Acrivon Therapeutics is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ACRV or DMAC more profitable? Acrivon Therapeutics' return on equity of -44.66% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -44.66% -40.94% DiaMedica Therapeutics N/A -61.35%-55.53% Does the media refer more to ACRV or DMAC? In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 1 articles in the media. DiaMedica Therapeutics' average media sentiment score of 1.89 beat Acrivon Therapeutics' score of 1.87 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Acrivon Therapeutics Very Positive DiaMedica Therapeutics Very Positive Which has higher valuation and earnings, ACRV or DMAC? DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$80.56M-$2.22-0.59DiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-5.67 Which has more volatility & risk, ACRV or DMAC? Acrivon Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. SummaryAcrivon Therapeutics beats DiaMedica Therapeutics on 9 of the 12 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.39M$2.42B$5.56B$9.10BDividend YieldN/A1.79%5.06%4.02%P/E Ratio-0.599.4228.2620.26Price / SalesN/A739.93427.70153.06Price / CashN/A164.4637.1257.67Price / Book0.234.608.045.49Net Income-$80.56M$31.26M$3.19B$250.45M7 Day Performance1.93%4.80%3.62%4.79%1 Month Performance10.00%8.17%5.98%9.59%1 Year Performance-82.28%-3.88%29.39%16.41% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics3.9578 of 5 stars$1.32-2.2%$17.71+1,242.0%-82.3%$41.39MN/A-0.5958Positive NewsDMACDiaMedica Therapeutics1.1902 of 5 stars$3.63-3.5%$8.00+120.4%+4.6%$161.24MN/A-5.6720High Trading VolumeNVCTNuvectis Pharma3.3682 of 5 stars$7.85+4.1%$17.00+116.6%+19.8%$157.54MN/A-6.958Positive NewsCGENCompugen1.7836 of 5 stars$1.72-2.3%$4.00+132.6%-9.7%$157.06M$27.86M-10.7570Positive NewsACRSAclaris Therapeutics2.2402 of 5 stars$1.46+1.4%$9.71+565.4%+18.9%$155.93M$18.72M-1.05100Analyst ForecastBIOABioAge LabsN/A$4.18-2.3%N/AN/A$153.44MN/A0.00N/AMOLNMolecular Partners3.1212 of 5 stars$3.61-4.0%$12.00+232.4%-42.6%$151.81M$2.23M-1.88180ALECAlector3.8871 of 5 stars$1.44-4.6%$4.00+177.8%-70.9%$150.99M$100.56M-1.14270News CoverageVTYXVentyx Biosciences3.5134 of 5 stars$2.04-1.9%$10.00+390.2%+7.0%$148.01MN/A-1.1730News CoveragePositive NewsLXEOLexeo Therapeutics2.3591 of 5 stars$4.54+2.0%$16.60+265.6%-74.6%$147.73M$650K-1.3858High Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+118.8%$147.14M$85.87M-39.63140Positive NewsEarnings ReportHigh Trading Volume Related Companies and Tools Related Companies DiaMedica Therapeutics Competitors Nuvectis Pharma Competitors Compugen Competitors Aclaris Therapeutics Competitors BioAge Labs Competitors Molecular Partners Competitors Alector Competitors Ventyx Biosciences Competitors Lexeo Therapeutics Competitors Theratechnologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
